2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVOX 2倍做多NVO ETF-Defiance

休市中 02-13 16:00:00 EST

18.90

+0.47

+2.55%

盘后18.92

+0.02+0.11%

19:35 EST

最高19.08	最低18.61	成交量32.44万
今开18.65	昨收18.43	日振幅2.55%
总市值5,288万	流通市值5,288万	总股本279.81万
成交额609.86万	换手率11.59%	流通股本279.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":18.9,"timestamp":1771016400000,"preClose":18.43,"halted":0,"volume":324382,"hourTrading":{"tag":"盘后","latestPrice":18.92,"preClose":18.9,"latestTime":"19:35 EST","volume":12832,"amount":243616.4613,"timestamp":1771029352288,"change":0.02,"changeRate":0.001058,"amplitude":0.008995},"delay":0,"changeRate":0.025501899077590824,"floatShares":2798101,"shares":2798101,"eps":0,"marketStatus":"休市中","change":0.47,"latestTime":"02-13 16:00:00 EST","open":18.65,"high":19.08,"low":18.61,"amount":6098577.526728,"amplitude":0.025502,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":18.43,"sharesOutstanding":2798101,"nav":18.44,"aum":51596982.44,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":18.58,"preClose":18.43,"latestTime":"09:26 EST","volume":20383,"amount":382598.163882,"timestamp":1770992815819,"change":0.15,"changeRate":0.008139,"amplitude":0.022789},"postHourTrading":{"tag":"盘后","latestPrice":18.92,"preClose":18.9,"latestTime":"19:35 EST","volume":12832,"amount":243616.4613,"timestamp":1771029352288,"change":0.02,"changeRate":0.001058,"amplitude":0.008995},"volumeRatio":0.5109766844034127,"impliedVol":0.7828,"impliedVolPercentile":0.468},"requestUrl":"/m/hq/s/NVOX/tweets","defaultTab":"tweets","newsList":[{"id":"2611152972","title":"诺和诺德明星减肥口服药上市第五周，处方量超3.8万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152972","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611152972?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:50","pubTimestamp":1770987013,"startTime":"0","endTime":"0","summary":"据路透社2月13日消息，IQVIA数据显示，丹麦制药公司诺和诺德（NVO.US）的明星减肥药Wegovy在上市第五周的处方量达到了38,220份。Wegovy是诺和诺德公司开发的一种用于治疗肥胖症的药物。自上市以来，该药物在美国市场的处方量持续增长，显示出其市场需求强劲。随着越来越多的医生和患者了解和认可Wegovy的疗效，预计其处方量还将进一步上升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213205119a4a0e331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213205119a4a0e331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","NVOH","NVOX","BK4585","BK4588","NVO","LU1093756325.SGD","LU1093756168.USD","BK4007","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2611145151","title":"诺和诺德(NVO)盘前涨超1% 拟扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2611145151","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611145151?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:06","pubTimestamp":1770984384,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前涨约1%，截至发稿，报48.960美元。消息面上，诺和诺德计划加大在爱尔兰的投资，在当地生产其畅销减肥药Wegovy的口服版本，以供应美国以外的市场。诺和诺德首席执行官迈克·杜斯达尔表示，诺和诺德将扩建其位于爱尔兰中部阿斯隆(Athlone)的生产设施。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NDkzODU1NDI1NzQyOTYxNg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDkzODU1NDI1NzQyOTYxNg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297189","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4588","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2611158296","title":"GLP‑1战场转至口服药：诺和诺德和礼来同时披露新的全球投资计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2611158296","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611158296?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:30","pubTimestamp":1770971414,"startTime":"0","endTime":"0","summary":"尽管诺和诺德在口服减重药的上市节奏上略占先机，但两家公司2月12日均披露了新的投资计划，以加速各自产品的全球推广。根据最新调查，许多患者因害怕注射而更倾向于选择口服药物。这一消息发布前一周，诺和诺德刚公布其减重药业务令人失望的销售指引，预计 2026 年总收入将下降 5%–13%，原因是来自礼来的竞争日益激烈。根据礼来此前的表态，公司预计将拥有足够库存，使该口服减重药能在多个国家几乎同步上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213171818a4a027f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213171818a4a027f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","IE00BJJMRY28.SGD","LU2746668974.SGD","SG9999018865.SGD","LU0471298777.SGD","LU2552382132.HKD","LU0823416689.USD","LU0238689110.USD","LU0882574055.USD","LU0471298694.HKD","LU2265009873.SGD","LU0889565916.HKD","IE00BJJMRX11.SGD","LU2456880835.USD","LU2491049909.HKD","LLYX","LU1035775433.USD","LU1629891620.HKD","NVOH","LU2237443978.SGD","BK4007","LU2089984988.USD","LU0787776722.HKD","IE00B775H168.HKD","IE00BKVL7J92.USD","SG9999015952.SGD","LU1057294990.SGD","BK4144","LU2271345857.HKD","LU2324357040.USD","LU2211815571.USD","SG9999014914.USD","SG9999017495.SGD","BK4534","IE00B2B36J28.USD","LU0122379950.USD","BK4533","LU0432979614.USD","LU1712237335.SGD","LU1868836757.USD","LU2461242641.AUD","LU2361044865.SGD","LU2468319806.SGD","LU2471134523.USD","LU2028103732.USD","LU1023059063.AUD","LU2112291526.USD","LU2237443622.USD","LU1983299246.USD","SG9999015945.SGD","IE00BK4W5M84.HKD","LU2063271972.USD","SGXZ51526630.SGD","IE00BK4W5L77.USD","IE00B4JS1V06.HKD","LU0106261372.USD","LU1280957306.USD","LU0353189763.USD","LU2089284900.SGD","LU2087625088.SGD","LLY","LU0061475181.USD","LU0094547139.USD","LU2756315318.SGD","LU1720051108.HKD","SG9999014906.USD","LU0289739699.SGD","IE00BFSS7M15.SGD","LU1868836591.USD","LU0203201768.USD","LU1145028129.USD","SG9999001176.USD","LU2471134952.CNY","LU0417517546.SGD","LU1868837136.USD","IE00B7KXQ091.USD","SGXZ57979304.SGD","SGXZ81514606.USD","LU0210536198.USD","LU2168564495.EUR","BK4532","IE00BJLML261.HKD","LU1989771016.USD","LU2361044949.HKD","LU2462157665.USD","SGXZ99366536.SGD","ELIL","LU2360106947.USD","LU0354030438.USD","LU2552382215.SGD","LU2111349929.HKD","LU0672654240.SGD","LU0320765059.SGD","IE0004445015.USD","LU2237438978.USD","LU1548497426.USD","IE0005OL40V9.USD","LU0683600562.USD","LU1551013425.SGD","LU0820561818.USD","LU0114720955.EUR","LU1814569148.SGD","LU0225283273.USD","LU2471134796.USD","LU2417539215.USD","LU2750360641.GBP","LU1061106388.HKD","LU0203202063.USD","LU1232071149.USD","LU1064131342.USD","LU2023250504.SGD","LU1551013342.USD","LU1868837300.USD","LU2213496289.HKD","LU2491050071.SGD","LU0158827948.USD","LU2089283258.USD","LU0079474960.USD","LU0198837287.USD","LU1093756168.USD","LU0323591593.USD","LU0109391861.USD","GB00BDT5M118.USD","LU0256863902.USD","LU0058720904.USD","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU2168564222.USD","LU0964807845.USD","LU2023250330.USD","LU2237443549.SGD","SG9999015986.USD","LU0097036916.USD","LU0823434583.USD","SGXZ31699556.SGD","LLYZ","BK4590","LU0256863811.USD","LU0943347566.SGD","LU1093756325.SGD","IE00BN29S564.USD","IE0002141913.USD","LU2896262040.SGD","LU0006306889.USD","LU0708995401.HKD","LU1127390331.HKD","BK4588","LU1267930730.SGD","LU1868836914.USD","LU2237443465.HKD","IE0009355771.USD","LU2552382058.USD","LU0820562030.AUD","LU2491050154.USD","LU1988902786.USD","NVOX","LU2237443895.HKD","LU2023251221.USD","IE00BKDWB100.SGD","LU0096364046.USD","BK4585","IE00BFTCPJ56.SGD","SG9999014880.SGD","LU0109394709.USD","LU2168564149.EUR","LU1623119135.USD","BK4581","LU2357305700.SGD","SG9999015978.USD","LU1720051017.SGD","SG9999018857.SGD","IE00BKPKM429.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","LU0786609619.USD","LU1069344957.HKD","LU1323610961.USD","LU2750360997.AUD","SG9999013999.USD","IE0004445239.USD","LU2756315664.SGD","LU1917777945.USD","LU2168563687.JPY","LU0689472784.USD","LU1974910355.USD","LU1366192091.USD","LU0882574139.USD","LU0266013472.USD","LU0320765992.SGD","LU0820561909.HKD","LU2361045086.USD","LU0823434740.USD","BK4599","LU0385154629.USD","LU2602419157.SGD","LU0234572021.USD","LU0466842654.USD","LU2106854487.HKD","LU2108987350.USD","LU1804176565.USD","LU2746668461.USD","IE00B4R5TH58.HKD","IE00BFSS8Q28.SGD","LU0316494557.USD","LU0456855351.SGD","ELIS","IE00B1XK9C88.USD","LU0640476718.USD","LU2168564065.EUR","SG9999014898.SGD","LU2264538146.SGD","LU0158827781.USD","LU2236285917.USD","LU0354030511.USD","LU0353189680.USD","LU1291159041.SGD","LU2237443382.USD","IE00BJJMRZ35.SGD","LU2471134879.HKD","BK4516","IE00BJT1NW94.SGD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2611113808","title":"礼来替尔泊肽国内第5项适应症落地，减肥药全球版图已成型，持续扩张中！","url":"https://stock-news.laohu8.com/highlight/detail?id=2611113808","media":"摩熵医药大数据","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611113808?lang=zh_cn&edition=full","pubTime":"2026-02-13 14:49","pubTimestamp":1770965382,"startTime":"0","endTime":"0","summary":"2月12日，$LLY礼来制药宣布，其GLP-1R/GIPR双重激动剂 替尔泊肽 在国内获批成人2型糖尿病单药治疗新适应症。截图来源：摩熵医药-全球药物研发数据库本次获批后，替尔泊肽 在国内适应症增至5项：T2DM联合治疗：二甲双胍/磺脲类疗效不佳者；T2DM单药治疗：本次新增，饮食运动基础上的成人患者；长期体重管理：BMI≥28（肥胖）或≥24；OSA治疗：成人肥胖患者中重度阻塞性睡眠呼吸暂停；T2DM联合胰岛素：联合胰岛素±口服降糖药控糖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213145638a49f9424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213145638a49f9424&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014898.SGD","BK4599","LU0385154629.USD","LU1629891620.HKD","LU1064131342.USD","LU2471134952.CNY","LU0289739699.SGD","SG9999013999.USD","LU1988902786.USD","LU2756315318.SGD","LU2746668974.SGD","LU0417517546.SGD","IE00BK4W5L77.USD","ELIS","LU2237438978.USD","IE00BFTCPJ56.SGD","LU2168563687.JPY","LU2168564222.USD","LU0466842654.USD","SG9999015986.USD","IE00BKDWB100.SGD","SG9999001176.SGD","SG9999014906.USD","LU2237443978.SGD","LU2111349929.HKD","LU2491050071.SGD","IE00BJT1NW94.SGD","BK4516","SG9999015945.SGD","LU0354030511.USD","LU2023251221.USD","LU1868837136.USD","LU0114720955.EUR","LU0471298694.HKD","LU0820561818.USD","LU2237443382.USD","LU2361045086.USD","LU2028103732.USD","NVOX","LU0882574055.USD","LU1868836591.USD","LU0823434740.USD","LU0689472784.USD","LU1267930730.SGD","LU0323591593.USD","SGXZ51526630.SGD","LU2237443622.USD","IE00BFSS8Q28.SGD","LU2023250330.USD","LU2468319806.SGD","LU0683600562.USD","LU2236285917.USD","LU2237443895.HKD","IE0004445239.USD","LU2552382058.USD","SGXZ99366536.SGD","NVOH","SGXZ57979304.SGD","IE00B775H168.HKD","LU0786609619.USD","LU1069344957.HKD","LU0210536198.USD","LU2491049909.HKD","BK4533","LU1983299246.USD","LU2168564495.EUR","SGXZ31699556.SGD","LU0109394709.USD","SG9999018865.SGD","LU0964807845.USD","LU1712237335.SGD","LU2087625088.SGD","IE0005OL40V9.USD","IE00BFSS7M15.SGD","LU0820562030.AUD","LU2237443549.SGD","IE00B1BXHZ80.USD","LU1814569148.SGD","IE00B4JS1V06.HKD","LU1868837300.USD","LU0256863902.USD","LU0353189680.USD","IE00BJJMRX11.SGD","LU0471298777.SGD","LU0353189763.USD","LU2213496289.HKD","LU2462157665.USD","LU2264538146.SGD","LU0234572021.USD","LU1061106388.HKD","LU1127390331.HKD","ELIL","LU2089284900.SGD","LU2271345857.HKD","LU0058720904.USD","LU2106854487.HKD","LU1551013342.USD","LU1548497426.USD","SG9999015952.SGD","BK4588","LLYX","LU2089283258.USD","LU0432979614.USD","IE00BN29S564.USD","LU1868836757.USD","LU0158827781.USD","IE00B7KXQ091.USD","SG9999014914.USD","LU1720051017.SGD","IE00BJJMRY28.SGD","LU0316494557.USD","LU0943347566.SGD","BK4007","LU1023059063.AUD","SG9999017495.SGD","BK4585","LU0097036916.USD","LU0354030438.USD","LU2023250504.SGD","SG9999018857.SGD","LU0006306889.USD","LU0640476718.USD","LU2456880835.USD","LU1057294990.SGD","IE00BKVL7J92.USD","LU1145028129.USD","LU0820561909.HKD","LU1974910355.USD","LU2361044949.HKD","LU0320765992.SGD","LU0225283273.USD","LU0154236417.USD","IE00B4R5TH58.HKD","LU2896262040.SGD","LU2750360997.AUD","LU0456855351.SGD","LU0320765059.SGD","IE0009355771.USD","LU1623119135.USD","LU2357305700.SGD","IE00B1XK9C88.USD","LU1323610961.USD","LU0203202063.USD","LU1093756168.USD","LU1989771016.USD","LU0203201768.USD","LU2265009873.SGD","BK4532","LU2746668461.USD","LU0198837287.USD","BK4581","LU0238689110.USD","LU1093756325.SGD","SGXZ81514606.USD","LU0106261372.USD","LU0061475181.USD","LU2168564149.EUR","LU0823434583.USD","SG9999015978.USD","LU0094547139.USD","LLYZ","LU2211815571.USD","LU2602419157.SGD","IE00B2B36J28.USD","LU2471134796.USD","LU1035775433.USD","LU2324357040.USD","LU2417539215.USD","IE00BJLML261.HKD","LU0158827948.USD","LU0889565916.HKD","LU0708995401.HKD","LU0823416689.USD","BK4534","LU1720051108.HKD","LU2756315664.SGD","LU2461242641.AUD","LU0266013472.USD","SG9999014880.SGD","LU2552382132.HKD","LU0122379950.USD","LU1232071149.USD","IE00BJJMRZ35.SGD","LU2237443465.HKD","GB00BDT5M118.USD","LU1804176565.USD","LU0079474960.USD","LU2750360641.GBP","LU2089984988.USD","LU2360106947.USD","LU0882574139.USD","LU2491050154.USD","LU0672654240.SGD","LU1868836914.USD","LU1917777945.USD","LLY","IE0004445015.USD","IE00BKPKM429.USD","LU2063271972.USD","LU2471134523.USD","LU2552382215.SGD","NVO","LU1291159041.SGD","LU1366192091.USD","IE0002141913.USD","LU0109391861.USD","LU2112291526.USD","LU2168564065.EUR","LU0096364046.USD","LU1280957306.USD","LU0256863811.USD","IE00BK4W5M84.HKD","LU2361044865.SGD","LU2471134879.HKD","SG9999001176.USD","IE00BWXC8680.SGD","IE00BZ1G4Q59.USD","LU2108987350.USD","LU1551013425.SGD","LU0787776722.HKD"],"gpt_icon":1},{"id":"2610781009","title":"诺和诺德起诉Hims 监管机构关注复方GLP1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2610781009","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610781009?lang=zh_cn&edition=full","pubTime":"2026-02-12 23:49","pubTimestamp":1770911340,"startTime":"0","endTime":"0","summary":"诺和诺德（NVO）周四早盘上涨1%。该公司提起诉讼，要求阻止Hims & Hers （HIMS） 销售复方司美格鲁肽，数日前美国食品药品监督管理局与卫生及公共服务部暗示将采取执法行动。Hims暂停口服制剂供应，周四早盘该股股价下跌1.5%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-12/doc-inhmqrvx6597100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4599","NVO","NVOH","BK4007","NVOX","BK4588","IE00BKVL7J92.USD","HIMS","BK4532","LU1093756168.USD","BK4585"],"gpt_icon":0},{"id":"2610794788","title":"剑指全球市场！诺和诺德(NVO.US)扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794788","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610794788?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:57","pubTimestamp":1770893858,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德计划加大在爱尔兰的投资，在当地生产其畅销减肥药Wegovy的口服版本，以供应美国以外的市场。诺和诺德首席执行官迈克·杜斯达尔表示，诺和诺德将扩建其位于爱尔兰中部阿斯隆的生产设施。杜斯达尔称，Wegovy口服药于1月初上市，成为有史以来最成功的药品首发之一，目前已有超过24万名美国患者服用。爱尔兰是全球制药制造中心之一。礼来在当地生产其重磅减肥和糖尿病药物的活性成分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"剑指全球市场！诺和诺德(NVO.US)扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0154236417.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4599","LU1093756325.SGD","NVOX","BK4007","NVO","BK4585","IE00BKVL7J92.USD","NVOH"],"gpt_icon":0},{"id":"2610197339","title":"贝伦贝格：将诺和诺德目标价下调至360丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2610197339","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610197339?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:27","pubTimestamp":1770877621,"startTime":"0","endTime":"0","summary":"贝伦贝格将诺和诺德目标价从415丹麦克朗下调至360丹麦克朗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260212/32014623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["NVOX","LU0154236417.USD","NVOH","BK4007","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","BK4532","BK4588","BK4585","BK4599","LU1093756168.USD"],"gpt_icon":0},{"id":"2610622339","title":"诺和诺德效仿礼来，将推出瓶装减重注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=2610622339","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610622339?lang=zh_cn&edition=full","pubTime":"2026-02-12 06:19","pubTimestamp":1770848393,"startTime":"0","endTime":"0","summary":"格隆汇2月12日｜诺和诺德计划推出瓶装（Vial）包装版本的减肥药 Wegovy，旨在夺回被竞争对手礼来抢走的客户。该公司计划先在美国市场推出瓶装版本，随后再推向全球其他国家，为患者提供更灵活的剂量选择。诺和诺德正依靠大幅降价来吸引患者。其Wegovy口服片剂直接面向消费者的售价已低至每月149美元，试图通过价格战重夺减重市场份额。礼来早在近两年前就推出了瓶装版本，以提供低价版制剂并缓解供应短缺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212062018a6f06da1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212062018a6f06da1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1551013425.SGD","GB00BDT5M118.USD","LU1720051108.HKD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU2491050154.USD","LLYZ","NVO","LU0316494557.USD","LU0238689110.USD","LU1623119135.USD","NVOH","LU0210536198.USD","SG9999014906.USD","LU0823434583.USD","LU2552382132.HKD","LU1868836757.USD","IE00BKVL7J92.USD","LU0820561909.HKD","LU0122379950.USD","LU1093756168.USD","LU2236285917.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU0471298777.SGD","LU0225283273.USD","LU0689472784.USD","LU2602419157.SGD","SG9999014914.USD","LU2360106947.USD","IE00B7KXQ091.USD","SGXZ31699556.SGD","LU0114720955.EUR","LU0198837287.USD","SG9999017495.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU0096364046.USD","LU2456880835.USD","SGXZ51526630.SGD","SG9999015952.SGD","LU2417539215.USD","SGXZ57979304.SGD","BK4516","LU0353189680.USD","LU0432979614.USD","LU0158827948.USD","LU1035775433.USD","IE00BWXC8680.SGD","LU2213496289.HKD","LU2023250330.USD","SG9999013999.USD","LU2111349929.HKD","LU0106261372.USD","LU0787776722.HKD","LU2168564149.EUR","LU2168564222.USD","LU2468319806.SGD","LU2237438978.USD","IE00B4JS1V06.HKD","LU2237443895.HKD","LU2023250504.SGD","LU2361044949.HKD","LU1868837136.USD","LU2750360641.GBP","LU0672654240.SGD","ELIL","LU1280957306.USD","LU2089984988.USD","LU0456855351.SGD","LU2237443465.HKD","LU2491050071.SGD","SG9999015978.USD","LU0466842654.USD","LU2361044865.SGD","LU2237443978.SGD","LU0289739699.SGD","IE00BKPKM429.USD","LU2271345857.HKD","LU0354030511.USD","IE00BN29S564.USD","LU0385154629.USD","LU0964807845.USD","LU1323610961.USD","BK4581","LU2462157665.USD","LU2756315664.SGD","IE00B1XK9C88.USD","LU1804176565.USD","BK4533","LU0683600562.USD","IE00BFSS7M15.SGD","LU1064131342.USD","LU1868837300.USD","LU2361045086.USD","LU1868836591.USD","SG9999014898.SGD","LU0079474960.USD","LU2168564495.EUR","SG9999014880.SGD","IE00BJJMRY28.SGD","LU1366192091.USD","LU2461242641.AUD","SG9999001176.SGD","LU2237443622.USD","SG9999018865.SGD","IE0005OL40V9.USD","LU0256863902.USD","LU0823416689.USD","LU2106854487.HKD","LU2264538146.SGD","LU2756315318.SGD","LLYX","LU0234572021.USD","LU0354030438.USD","LU0256863811.USD","IE0002141913.USD","LLY","LU1093756325.SGD","IE00BJLML261.HKD","LU0094547139.USD","LU0353189763.USD","LU0471298694.HKD","LU1974910355.USD","LU0097036916.USD","LU1127390331.HKD","LU1551013342.USD","LU2087625088.SGD","LU0266013472.USD","LU0943347566.SGD","LU2108987350.USD","LU0786609619.USD","ELIS","LU2211815571.USD","LU0708995401.HKD","LU0823434740.USD","BK4585","BK4599","LU0882574055.USD","BK4532","LU2168564065.EUR","IE00BK4W5M84.HKD","LU1291159041.SGD","LU1548497426.USD","LU2896262040.SGD","LU0061475181.USD","LU0417517546.SGD","LU2112291526.USD","LU1069344957.HKD","LU0006306889.USD","SGXZ99366536.SGD","LU2552382058.USD","LU0820562030.AUD","BK4007","LU1720051017.SGD","SG9999015945.SGD","LU0820561818.USD","LU1989771016.USD","LU2471134796.USD","LU2023251221.USD","LU2324357040.USD","BK4588","LU2552382215.SGD","LU2265009873.SGD","IE0004445015.USD","LU0154236417.USD","LU0320765992.SGD","LU0882574139.USD","LU0058720904.USD","SG9999018857.SGD","LU0320765059.SGD","LU2237443549.SGD","LU2471134523.USD","LU0109391861.USD","LU1267930730.SGD","LU1814569148.SGD","LU2168563687.JPY","LU2750360997.AUD","LU2089284900.SGD","LU2237443382.USD","LU1232071149.USD","IE00B775H168.HKD","LU1712237335.SGD","LU1868836914.USD","LU1145028129.USD","LU0203201768.USD","LU0640476718.USD","LU1023059063.AUD","LU2089283258.USD","LU2357305700.SGD","LU0203202063.USD","LU1917777945.USD","LU1983299246.USD","LU0323591593.USD","LU1629891620.HKD","LU2746668461.USD","BK4534","IE0009355771.USD","LU0158827781.USD","IE00BJJMRX11.SGD","SGXZ81514606.USD","IE0004445239.USD","LU2028103732.USD","NVOX","IE00BJJMRZ35.SGD","IE00BFSS8Q28.SGD","SG9999001176.USD","IE00BZ1G4Q59.USD","LU2471134879.HKD","IE00BKDWB100.SGD","LU0109394709.USD","LU2063271972.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU2746668974.SGD","SG9999015986.USD","IE00B1BXHZ80.USD","LU2471134952.CNY","IE00BK4W5L77.USD","LU1988902786.USD"],"gpt_icon":0},{"id":"2610935665","title":"德银：诺和诺德仍有机会重新把握肥胖症市场的机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610935665","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610935665?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:28","pubTimestamp":1770805680,"startTime":"0","endTime":"0","summary":"德意志银行分析师Emmanuel Papadakis写道，诺和诺德在适当的时候仍有机会重新把握其在肥胖症市场的机遇。该行仍对诺和诺德持乐观看法，该股市盈率已回落至十几倍的水平。　　该公司Wegovy口服药的上市表现稳健，下半年有潜在的销量利好因素，而且或许最重要的是，关键的cagrisema数据仍有待公布。　　该行将该股目标价从475丹麦克朗下调至400丹麦克朗，并维持买入评级。该股下跌2.4%，至307.55丹麦克朗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmmvza3702737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1093756325.SGD","LU0154236417.USD","BK4588","NVO","IE00BZ1G4Q59.USD","NVOH","NVOX","BK4585","BK4599","BK4007","IE00BKVL7J92.USD","LU1093756168.USD","BK4532"],"gpt_icon":0},{"id":"2610098986","title":"德银：将诺和诺德目标价下调至400丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2610098986","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610098986?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:30","pubTimestamp":1770795023,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"96dea5df3652c556a4b5cab9408231f9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1093756325.SGD","LU0154236417.USD","BK4588","NVO","IE00BZ1G4Q59.USD","NVOH","NVOX","BK4585","BK4599","BK4007","IE00BKVL7J92.USD","LU1093756168.USD","BK4532"],"gpt_icon":0},{"id":"2610612515","title":"诺和诺德减重药广告被指误导消费者，FDA发出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2610612515","media":"第一财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610612515?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:12","pubTimestamp":1770711166,"startTime":"0","endTime":"0","summary":"但诺和诺德称，FDA的最新警告不涉及超级碗广告，而是常规播放的关于司美格鲁肽口服减重药电视广告。去年年底，司美格鲁肽口服减重药获得美国FDA批准，成为全球首个获批上市的GLP-1类口服减重药，早于竞争对手礼来。在FDA的警告信中，监管机构认为，诺和诺德的电视广告误导性地暗示，与其他GLP-1类减重药相比，司美股鲁肽口服减重药效果更佳。FDA要求诺和诺德立即采取行动解决这种违规行为，包括停止所有包含误导性信息的广告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016173295408f1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016173295408f1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK4585","BK4588","LU1093756168.USD","LU1093756325.SGD","NVOH","BK4007","LU0154236417.USD","BK4532","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOX"],"gpt_icon":0},{"id":"2610961801","title":"药王易主、山寨药搅局、专利悬崖倒计时、被指虚假宣传，诺和诺德全球防线告急","url":"https://stock-news.laohu8.com/highlight/detail?id=2610961801","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610961801?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:06","pubTimestamp":1770703564,"startTime":"0","endTime":"0","summary":"作为全球糖尿病与肥胖症治疗领域的绝对巨头，诺和诺德曾凭借司美格鲁肽系列产品缔造医药行业的增长神话，市值一度登顶欧洲上市公司榜首。然而进入2026年，这家丹麦制药巨头却遭遇开年暴击：明星产品司美格鲁肽仅以4亿美元之差痛失“全球药王”宝座，美国市场突现低价“山寨”司美格鲁肽搅局，口服减肥药被FDA指为虚假宣传，叠加专利悬崖倒计时的大背景，诺和诺德全球防线告急。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602103646576715.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646576715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756168.USD","BK4599","BK4585","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LLY","LU1093756325.SGD","LU0154236417.USD","BK4588","BK4007","BK4532","NVOX","NVO"],"gpt_icon":0},{"id":"2610693315","title":"诺和诺德：GLP-1/GIP/GCG启动减重二期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693315","media":"医药笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610693315?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:25","pubTimestamp":1770683156,"startTime":"0","endTime":"0","summary":"UBT251为联邦制药自主研发的GLP-1/GIP/GCG受体激动剂。2025年3月，联邦制药宣布将GLP-1/GIP/GCG受体激动剂UBT251的大中华区外全球权益授权给诺和诺德，后者支付2亿美元预付款、18亿美元里程碑金额，以及一定比例的销售分成。总结2025年12月，礼来公布GLP-1/GIP/GCG三靶点激动剂Retatrutide首个三期临数据，治疗肥胖合并骨关节炎三期临床TRIUMPH-4的最新数据，9mg、12mg Retatrutide治疗68周减重幅度分别为26.4%、28.7%，安慰剂组减重2.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021008564095407eb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021008564095407eb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","NVO","BK4585","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","BK4590","BK4588","BK4532","NVOH","BK4144","BK4007","LU0154236417.USD","NVOX","LU1093756168.USD","03933"],"gpt_icon":0},{"id":"2610662731","title":"365亿美元新“药王”诞生：代谢病主导时代开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2610662731","media":"新快报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610662731?lang=zh_cn&edition=full","pubTime":"2026-02-10 07:15","pubTimestamp":1770678931,"startTime":"0","endTime":"0","summary":"2025年全球“药王”权杖完成里程碑式交接。1决战2025年四季度，新“药王”实现反超礼来公司的GLP-1/GIP双靶点激动剂替尔泊肽以365.07亿美元的年销售额，从诺和诺德和默沙东手中夺走了“药王”头衔。这种差异直接推动了全球“药王”权杖从肿瘤领域向代谢疾病领域的转移。3GLP-1赛道激战正酣新“药王”的诞生正在改变全球药物研发的资金流向和战略重点。62026年“药王”已被提前锁定替尔泊肽已提前锁定2026年销量冠军。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210072652a6e7b870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210072652a6e7b870&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BBT3K403.USD","LU0234572021.USD","LU0432979614.USD","LU1983299246.USD","LU1037948897.HKD","LU0266013472.USD","LU1571399168.USD","IE00BN8TJ469.HKD","LU1989772840.SGD","LU1116320901.HKD","LU1023059063.AUD","LU1093756168.USD","BK4559","LU0965509010.AUD","LU1035773651.USD","LU2089984988.USD","BK4550","BK4585","LU1291159041.SGD","LU1941712348.USD","LU0106261372.USD","BK4159","LU1934455194.USD","LU0154236417.USD","IE00B4R5TH58.HKD","LU0648001328.SGD","BK4534","LU2361044865.SGD","LU2361044949.HKD","LU1934455863.HKD","IE0002141913.USD","BK4533","LU0211331839.USD","LU1093756325.SGD","LU1162221912.USD","SG9999014575.USD","LU0265550946.USD","LU0130517989.USD","LU1941712264.USD","LU2361045086.USD","LU1917777945.USD","LU1066051498.USD","LU2023250843.SGD","LU0965508806.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","SG9999002224.SGD","LU1989771016.USD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","SGXZ57979304.SGD","LU1699723380.USD","SG9999002232.USD","IE000M9KFDE8.USD","LU1037948541.HKD","LU1934455277.USD","BK4532","SG9999015341.SGD","LU1066051225.USD","LU1430594728.SGD","LU1989772923.USD","SG9999001176.SGD","BK4599","IE0009355771.USD","LU0006306889.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","SG9999015358.SGD","LU1585245621.USD","LU0265550359.USD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU0122379950.USD","LU0098860793.USD","LU2125154778.USD","LU1929549753.HKD","LU1066051811.HKD","LU0203347892.USD","LU0965509283.SGD","LU2468319806.SGD","SG9999013999.USD","LU2360032135.SGD","NVOX","SG9999001440.SGD","LU2461242641.AUD","MRK","SG9999001176.USD","LU0477156953.USD","LU0861579265.USD","IE00BKVL7J92.USD","LU1974910355.USD","BK4516","LU1069347547.HKD","LU0289739699.SGD","IE00B2B36J28.USD","BK4588","LU1116320737.USD","NVOH","LU0238689110.USD","LU0980610538.SGD","SG9999014567.USD","LU0965509101.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","LU0130102774.USD","SG9999014559.SGD","LLY","IE00BSNM7G36.USD","LU2023250504.SGD","LU0058720904.USD","LU0208291251.USD","LU1066053197.SGD","LU1201861249.SGD","LU2125154935.USD","SG9999014542.SGD","LU2324357040.USD","NVO","LU1061106388.HKD","LU0985320562.USD","LU0203345920.USD","LU2106854487.HKD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2610651923","title":"Hims撤销Wegovy仿制计划 股价暴跌26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610651923","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610651923?lang=zh_cn&edition=full","pubTime":"2026-02-09 23:01","pubTimestamp":1770649260,"startTime":"0","endTime":"0","summary":"Hims & Hers（HIMS）周一早盘暴跌26.2%。鉴于FDA审查及法律风险，该公司已取消销售复合司美格鲁肽药片计划，诺和诺德（NVO）股价上涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-09/doc-inhmfumc9074317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVO","SINA","BK4585","BK4588","LU1093756168.USD","BK4196","LU1093756325.SGD","NVOH","BK4007","HIMS","LU0154236417.USD","BK4532","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOX"],"gpt_icon":0},{"id":"2610659393","title":"美股低开 减肥药概念股普涨 诺和诺德涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610659393","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610659393?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:32","pubTimestamp":1770647542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOX","LU1093756168.USD","TNA","UWM","NVO","IE00BKVL7J92.USD","IWO","BK4599","LU1093756325.SGD","BK4588","SRTY","RWM","BK4007","LU0154236417.USD","NVOH","IWN","HIMS","BK4585","BK4535","BK4534","BK4532","BK4550","MNQmain","IE00BZ1G4Q59.USD","BK4581","LLY","TZA","TWM"],"gpt_icon":0},{"id":"2610659660","title":"诺和诺德盘中异动 早盘股价大涨4.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610659660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610659660?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:31","pubTimestamp":1770647516,"startTime":"0","endTime":"0","summary":"北京时间2026年02月09日22时31分，诺和诺德股票出现波动，股价急速拉升4.51%。诺和诺德股票所在的制药行业中，整体涨幅为1.48%。其相关个股中，博美集团、Ironwood医药、诺和诺德涨幅较大，苏轩堂、Biofrontera Inc.、Hims & Hers Health, Inc.较为活跃，换手率分别为370.69%、74.08%、4.55%，振幅较大的相关个股有Biofrontera Inc.、苏轩堂、Ironwood医药，振幅分别为15.47%、11.33%、6.14%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209223156a48f9a2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209223156a48f9a2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4599","NVOX","BK4588","LU1093756325.SGD","BK4007","NVOH"],"gpt_icon":0},{"id":"2610350655","title":"司美格鲁肽减肥针研发企业起诉Hims & Hers 后者推出49美元减肥丸产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2610350655","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610350655?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:04","pubTimestamp":1770642252,"startTime":"0","endTime":"0","summary":"此次诉讼由诺和诺德向美国特拉华州地区法院提起，距离Hims & Hers宣布计划以每月49美元的首发价销售司美格鲁肽减肥针复方仿制药还不到一周。美国食品药品监督管理局此前已对Hims & Hers发出行动警告，该公司遂于2月7日宣布，将停止销售这款司美格鲁肽减肥针复方仿制药。针对这起诉讼，Hims & Hers的代表尚未立即回应《今日美国》的相关问询。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209210753a48f54c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","NVOH","BK4599","NVOX","HIMS","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","BK4007","BK4532","BK4588"],"gpt_icon":1},{"id":"2610637128","title":"诺和诺德：已对Hims & Hers公司的仿制产品提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637128","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610637128?lang=zh_cn&edition=full","pubTime":"2026-02-09 20:09","pubTimestamp":1770638970,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"961f70a84cc7ef0c9ed061f364f6809e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOX","LU0154236417.USD","NVOH","BK4007","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","BK4532","BK4588","BK4585","BK4599","LU1093756168.USD","HIMS"],"gpt_icon":0},{"id":"2610164632","title":"诺和诺德欧股大涨9%，竞争对手取消仿制Wegovy减肥药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2610164632","media":"华尔街见闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610164632?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:47","pubTimestamp":1770637622,"startTime":"0","endTime":"0","summary":"诺和诺德股价反弹超8%，主因远程医疗公司Hims & Hers在监管压力下撤销低价仿制减肥药计划，缓解了市场对GLP-1药物被廉价替代的担忧。但公司仍面临“前所未有的价格压力”，市值较2024年峰值已缩水近三分之二，来自礼来等对手的竞争与长期定价挑战依然严峻。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3765309","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"f7c0bd47606c6d38ed63371867a97d11","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3765309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","LU1093756325.SGD","NVO","BK4588","IE00BKVL7J92.USD","BK4532","BK4585","NVOX","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4007","NVOH","BK4599"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0745},{"period":"1month","weight":-0.3469},{"period":"3month","weight":-0.0771},{"period":"6month","weight":-0.264},{"period":"1year","weight":-0.7497},{"period":"ytd","weight":-0.1366}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"2倍做多NVO ETF-Defiance","nameEN":"Defiance Daily Target 2X Long NVO ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"2倍做多NVO ETF-Defiance,NVOX,2倍做多NVO ETF-Defiance股票,2倍做多NVO ETF-Defiance股票老虎,2倍做多NVO ETF-Defiance股票老虎国际,2倍做多NVO ETF-Defiance行情,2倍做多NVO ETF-Defiance股票行情,2倍做多NVO ETF-Defiance股价,2倍做多NVO ETF-Defiance股市,2倍做多NVO ETF-Defiance股票价格,2倍做多NVO ETF-Defiance股票交易,2倍做多NVO ETF-Defiance股票购买,2倍做多NVO ETF-Defiance股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}